The Xenazine Formula: Is it a Viable Model for Others?
This article was originally published in RPM Report
Executive Summary
Despite its ultra-orphan indication, Xenazine is likely to provide a very attractive return on its development costs. It's a model that could work for other drugs-but only when several key factors work together.